EGFR and cancer: Mechanistically, YY1 transcriptionally up‐regulates IL32 secretion from PCs, which then activates the β5‐integrin‐Src‐Akt signaling pathway in EGFR‐mutant cancer cells to confer their TKI sensitivity.